<DOC>
	<DOCNO>NCT00933309</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Avandamet give combination exemestane patient obese postmenopausal hormone-receptive-positive breast cancer spread part body .</brief_summary>
	<brief_title>The Impact Obesity Obesity Treatments Breast Cancer</brief_title>
	<detailed_description>The Study Drugs : Exemestane decrease ability estrogen help cancer cell grow . This could cause cancer cell die . Avandamet contain two drug commonly use control blood sugar level patient diabetes ( metformin rosiglitazone ) . If find eligible take part study , dose Avandamet receive depend join study . The first group participant receive low dose level Avandamet . Each new group receive high dose Avandamet group , intolerable side effect see . This continue high tolerable dose Avandamet find . All participant receive dose level exemestane . Study Drug Administration : The study drug ( ) give 28-day `` cycle . '' You take exemestane tablet mouth every day . You also take tablet Avandamet mouth 1 2 time day depend dose level assign . You take Avandamet meal . Study Visits : On Day 1 Cycles 2 , 3 , 4 , every 3 month , follow test procedure perform : - You physical exam , include measurement weight vital sign . - You ask side effect may . - You ask drug may take may take . - You performance status evaluation . - Blood ( 1-2 teaspoon ) draw routine test . This blood draw do 3 day cycle . - Blood ( 1 teaspoon ) draw blood sugar test . If history diabetes , need fast 8 hour blood sugar test . Every 3 month , scan check status disease . The scan perform depend disease locate body . Every 3 month , also echocardiogram ( ECHO ) multi-gated acquisition ( MUGA ) scan test heart function . Additional Blood Draws : Blood ( 1 teaspoon time ) also draw pharmacokinetic ( PK ) test . PK test measure amount study drug ( ) body different time point . Blood drawn PK test take study drug ( ) 1 , 3 , 6 , 12 , 23 hour take study drug ( ) Days 1 , 8 , 15 Cycle 1 . Length Study : You may take study drug ( ) long disease stable and/or respond . You may take study disease get bad intolerable side effect occur . This investigational study . Exemestane Avandamet FDA approve commercially available . Exemestane approve treatment metastatic breast cancer . Avandamet approve treatment diabetes . The use drug combination investigational . Up 24 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>1 . Overweight obese postmenopausal woman history biopsyproven estrogen receptor positive and/or progesterone receptor positive breast cancer clinical evidence metastatic disease . Overweight obesity define WHO BMI 25 29.9 &gt; /= 30 kg/m^2 respectively . Postmenopausal status define one following : ) spontaneous menses 1 year , woman &gt; 55 year ; Continued inclusion criterion # 2 . 2 . Continuation inclusion # 1 : b ) spontaneous menses within past 1 year woman &lt; /= 55 year postmenopausal gonadotrophin level ( LH FSH level &gt; 40 IU/L ) postmenopausal estradiol level ( &lt; 10 pg/mL ) ; c ) bilateral oophorectomy . 3 . Prior endocrine therapy , biologic therapy chemotherapy allow , either adjuvant setting metastatic breast cancer . 4 . Prior exemestane , metformin , rosiglitazone allow take longer 7 day prior enrollment . 5 . Localized radiotherapy , influence signal evaluable lesion , allow prior initiation study medication . 6 . Performance status &lt; /= 2 ECOG . 7 . Absolute neutrophil count ( ANC ) &gt; /= 1000/µl , platelet &gt; /= 75,000/µl , hemoglobin &gt; /= 8.5 gm/dL ; serum creatinine &lt; 1.4 mg/dL ; bilirubin &lt; 1.8 mg/dL ; ALT AST &lt; /= 2.5 x ULN demonstrable liver metastasis &lt; /= 5 x ULN presence liver metastases ; alkaline phosphatase &lt; 3 x upper limit normal ; calcium &lt; /= 11.0 mg/dL . 8 . Patients must competent give inform consent state understand investigational nature propose treatment . 1 . Extensive radiotherapy within previous 4 week ( great equal 30 % marrowbearing bone , e.g. , whole pelvis half spine ) . 2 . Uncontrolled diabetes mellitus ( hemoglobin A1C &gt; 9 random plasma glucose &gt; 400 mg/dL ) . 3 . History acromegaly , Cushing 's syndrome , Cushing 's disease , Addison 's disease ( treat untreated ) . 4 . Patients unstable angina , uncontrolled ischemic cardiac disease symptomatic congestive heart failure ( e.g . Class III IV New York Heart Association 's Functional Classification ) . 5 . Concurrently receive unwilling discontinue hormonal ( estrogen without progesterone ) replacement therapy . 6 . Other investigational drug within past 3 week concurrently . 7 . Patients know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . 8 . Laboratory result sustain : International normalized ratio ( INR ) &gt; 1.6 ; ALT AST &gt; 2.5 x ULN demonstrable liver metastasis &gt; 5 x ULN presence liver metastasis ; No 3 retests within screen period 9 . Patients know diagnosis human immunodeficiency virus ( HIV ) infection . 10 . Patients receive chemotherapy within 3 week ( 6 week nitrosourea mitomycinC ) . Acute toxicity prior therapy must resolve Grade &lt; /= 1 exception fatigue , alopecia , anemia . 11 . Any severe concomitant condition make undesirable patient participate study would jeopardize compliance protocol e.g. , severe renal hepatic impairment currently unstable uncompensated respiratory cardiac condition . 12 . History hypersensitivity active inactive excipients study medication exemestane metformin . 13 . Untreated clinically unstable central nervous system involvement . A patient adequately treat brain metastasis would eligible one month completion surgery and/or radiation therapy clinically stable .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Breast</keyword>
	<keyword>Obese</keyword>
	<keyword>Obesity Treatment</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Aromasin</keyword>
	<keyword>Metformin Rosiglitazone</keyword>
	<keyword>Avandamet</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Hormone-sensitive</keyword>
	<keyword>Hormone-receptive-positive breast cancer</keyword>
</DOC>